MCKESSON CORP

McKesson Corporation announced its second-quarter fiscal year 2027 financial results, reporting a net income of $1.30 billion, or $10.44 per diluted share, an increase from $1.16 billion, or $8.92 per diluted share, in the same period last year. Revenues for the quarter rose to $110.96 billion from $103.15 billion year-over-year. The company also noted an increase in total assets to $92.32 billion. Restructuring charges were $85 million for the quarter.

McKesson Corporation reported mixed financial results for the three months ended June 30, 2026, with revenues increasing to $105,380 million, but net income attributable to McKesson Corporation decreasing 21.7% to $614 million, and diluted EPS falling 17.6% to $5.15. The company completed the sale of a 13% minority ownership interest in its Medical-Surgical Solutions business for approximately $1.25 billion and incurred higher restructuring charges of $136 million. Net cash used in operating activities improved significantly to $(220) million.

McKesson Corporation reported strong first-quarter fiscal 2027 results, with consolidated revenues increasing 8% to $105.4 billion and Adjusted Earnings per Diluted Share growing 20% to $9.93. Following this performance, the company raised its full-year fiscal 2027 Adjusted EPS guidance range to $44.20-$45.00. McKesson also announced a 15% increase in its quarterly dividend to $0.94 per share and returned $2.6 billion to shareholders. Progress was also noted in the planned separation of its Medical-Surgical Solutions segment, which has been named Wellverse.

McKesson Corporation announced the retirement of Thomas L. Rodgers, Executive Vice President, Chief Strategy and Business Development Officer, effective August 1, 2026. To ensure a smooth transition, the company has appointed Ramesh Srinivasan as Executive Vice President, Chief Strategy Officer, with his appointment also effective August 1, 2026.

McKesson Corporation has filed its DEF 14A proxy statement, announcing its 2026 Annual Meeting of Shareholders to be held virtually on July 22, 2026. Key items of business include the election of 11 directors, ratification of Deloitte & Touche LLP as the independent auditor, and an advisory vote on executive compensation. The filing also details changes in Board leadership, with Brian S. Tyler becoming Chair of the Board and Dominic J. Caruso appointed as Lead Independent Director. The company highlights its 'Leadership Prescription' framework, focusing on people and culture, and its strategic priorities for advancing health outcomes.

McKesson Corporation announced that its subsidiary, McKesson Medical-Surgical Top Holdings, Inc., entered into an amendment to its Credit Agreement to establish a $2,250.0 million senior secured term "B" loan facility due 2032. The new facility will bear interest at either the Adjusted Term SOFR Rate plus 2.25% or the Base Rate plus 1.25%, with the company initially selecting the SOFR-based rate. The obligations are secured by substantially all assets of the borrower and its material U.S. subsidiaries, and the borrower will adhere to financial covenants related to leverage and interest coverage.

McKesson Corporation announced a new four-segment reporting structure in fiscal 2026, comprising North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company intends to separate its Medical-Surgical Solutions segment into an independent company, with Apollo Funds acquiring a 13% minority ownership interest for approximately $1.25 billion. Additionally, McKesson completed the sale of its Norwegian operations during fiscal 2026, reflecting strategic initiatives to focus on core healthcare businesses.

McKesson Corporation reported strong preliminary results for Q4 and full fiscal year ended March 31, 2026, with consolidated revenues increasing 6% to $96.3 billion in Q4 and 12% to $403.4 billion for the full year. Adjusted diluted EPS rose 16% to $11.69 for Q4 and 18% to $39.11 for the full year, exceeding long-range targets. The company also announced a $5.0 billion increase to its share repurchase program, bringing the total authorization to $7.7 billion, and provided fiscal 2027 Adjusted EPS guidance of $43.80 to $44.60.

McKesson Corporation and certain subsidiaries entered into a new Credit Agreement on April 24, 2026. This agreement establishes a $5 billion revolving credit facility, with Bank of America, N.A. acting as the Administrative Agent. The facility also includes an Alternative Currency Sublimit of $4.5 billion, providing flexible financing options for the company's operations.

McKesson Medical-Surgical Top Holdings Inc., a subsidiary of McKesson Corporation, has entered into a credit agreement with JPMorgan Chase Bank, N.A., and other lenders. This agreement provides McKesson with access to loans and credit facilities, which can be used for various corporate purposes, including working capital, acquisitions, and capital expenditures. The new credit agreement provides financial flexibility for McKesson.